A higher PTEN deletion rate by FISH (41 %) was only reported from a study on 199 highly selected metastatic breast cancers [28], as well as from heterozygosity (LOH) studies, reporting PTEN deletion in 30 %–41 % of 22–105 analyzed breast cancers [29–33]. This evidence concerns the gene PTEN and breast carcinoma.